• Latest

1. PI, General Research Fund 2024/25, Unraveling the immunoregulatory role of sympathetic innervation in cancer liver metastases. RGC, HK$1,559,580.

2. PI, General Research Fund 2023/24, Deciphering T helper-2 cell immunity in cancer liver metastasis-associated immunotherapy resistance. RGC, HK$1,523,774. 

3. PI, General Research Fund 2022/23, Mechanistic delineation of hepatoma-intrinsic FADD in modulating anti-tumor CD8+T cell response. RGC, HK$883,197. 

​

• 2022-2023

1. Co-I, General Research Fund 2021/22, Targeting epigenetic vulnerability in immunosuppressive myeloid cells to overcome immunotherapy resistance in hepatocellular carcinoma. RGC, HK$1,170,652. 

​

• 2021-2023

1. Co-I, AstraZeneca Oncology Pre-clinical Research Programme 2020, Overcoming the PD-1/PD-L1 therapeutic resistance in hepatocellular carcinoma by BET inhibitor. AstraZeneca, HK$400,000. 

2. PI, General Research Fund 2020/21, Delineating the immunoregulatory role of cholesterol on natural killer T cells in cancer liver metastases. RGC, HK$996,285. 

3. Co-I, General Research Fund 2020/21, Resistance to immune checkpoint targeting in hepatocellular carcinoma: Role of tumor interferon signaling. RGC, HK$1,195,542. 

​

• 2020-2022

1. PI, Health and Medical Research Fund 2020, Improving liver cancer immunotherapy by co-targeting monocytic myeloid-derived suppressor cells. FHB, HK$1,000,000. 

​

• 2020-2021

1. PI, General Research Fund 2019/20, Mechanistic delineation of myeloid CCRK signaling in tumor immunosuppression’. RGC, HK$1,004,845. 

2. Co-I, General Research Fund 2019/20, Molecular and functional characterization of the immunoregulatory CCRK-mTOR pathway in NAFLD-associated hepatocellular carcinoma. RGC, HK$1,049,917. 

​

• 2019-2020

1. Co-I, Health and Medical Research Fund 2019, A novel liver-specific PD-L1-trap nanoparticle for hepatocellular carcinoma immunotherapy. FHB, HK$1,187,900. 

2. Co-I, AstraZeneca Oncology Pre-clinical Research Programme 2019, Targeting the immunosuppressive tumor microenvironment by CXCR2 blockade for hepatocellular carcinoma therapy. AstraZeneca, HK$100,000. 

3. Co-I, BMS Pre-clinical Program 2019, Investigating the efficacy and mechanistic basis of BET and PD-                                        1/PD-L1 co-blockade in fibrosis-associated hepatocellular carcinoma. BMS, HK$100,000. 

​

• 2018-2021

1. Co-I, Terry Fox Foundation 2018, Functional dissection of fibrosis-induced monocytic myeloid-derived suppressor cells to develop new combination immunotherapy for hepatocellular carcinoma. Terry Fox Foundation, HK$1,200,000. 

​

• 2017-2019

1. PI, AstraZeneca Oncology Pre-clinical Research Programme 2017, Enhancement of Hepatocellular Carcinoma Immunotherapy through mTOR Inhibition. AstraZeneca, HK$400,000.

 

• 2016-2018

1. PI, Health and Medical Research Fund 2016, Elucidating the immunoregulatory role of the oncogenic cell-cycle related kinase in obesity-related hepatocellular carcinoma. FHB, HK$1,199,668.